Down-regulation of EGFL8 regulates migration, invasion and apoptosis of hepatocellular carcinoma through activating Notch signaling pathway

Table 1 Correlations between the down-regulation of EGFL8 and clinico- pathological features of hepatocellular carcinoma

			Down-regulation of Egfl8
Clinicopathological features	Variables	n	Positive	Negative	P-Value^†
Gender	Male	80	60	20	0.828
Gender	Female	22	16	6	0.828
Age	≥ 65 years	44	34	10	0.650
Age	< 65 years	58	42	16	0.650
Etiology	HBV infection	71	54	17	0.154
	HCV infection	9	6	3
	Other or rare cause	22	12	10
Liver cirrhosis	Presence	65	51	14	0.245
Liver cirrhosis	Absence	37	25	12	0.245
Serum AFP level	≥ 20 μg/L	60	43	17	0.494
Serum AFP level	< 20 μg/L	42	33	9	0.494
Maximal tumor size	≥ 5 cm	63	50	13	0.168
Maximal tumor size	< 5 cm	39	26	13	0.168
Edmondson-Steiner grade	I – II	71	54	17	0.626
Edmondson-Steiner grade	III – IV	31	22	9	0.626
Capsular formation	Presence	57	39	18	0.169
Capsular formation	Absence	45	37	8	0.169
Tumor nodule number	Solitary	61	40	21	0.019^*
Tumor nodule number	Multiple (≥2)	41	36	5	0.019^*
Vein invasion	Presence	46	40	6	0.012^*
Vein invasion	Absence	56	36	20	0.012^*
TNM stage^a	I – II	52	34	18	0.031^*
TNM stage^a	III – IV	50	42	8	0.031^*

^† The P-values were obtained from Chi-square test or Fisher’s exact test and all tests were two-sided. ^aTNM classification is according to 8th Edition of the AJCC (American Joint Committee on Cancer) Cancer Staging Manual. *, P < 0.05. EGFL8:epidermal growth factor-like domain; AFP α-fetoprotein, HBV Hepatitis B virus, HCV Hepatitis C virus

ISSN: 1471-2407